Biotech, Food & Drug

In today’s hyper-aware environment, concerns about food and drug safety are paramount for both companies and consumers.  The Food and Drug Administration (FDA) and the US Department of Agriculture (USDA) regulates the areas of biotech, food, and drug law. Additionally, laws including the 21st Century Cures Act, and cGMP (Current Good Manufacturing Processes), regulate industry standards/norms in food, cosmetics, and other industry-sectors. Visitors to the National Law Review will find the latest analysis of news, legislation, and upcoming cases/litigation as it relates to this area of law.

With researchers searching for new energy solutions and other developments in biotech, visitors to the NLR will have the opportunity to read content surrounding biosimilars, natural fuel production, medical devices, biotechnology, nanotechnology and materials, and the pharmaceuticals industry. Additionally, content relating to food and drug laws, limits on chemical use in cosmetic products, and other general health/safety topics are covered by the National Law Review and are updated regularly. Additionally, food safety and imports to the United States are also discussed as they become relevant. 

In addition to general health, science, and food/drug, the industry is also closely related to many of the issues related to intellectual property law. New applications for patents, intellectual property, licensing laws, and other areas which are governed by the PTAB court, often crossover into the industry.

New developments in legislation, including the legalization of recreational marijuana has created a new area ripe for legal analysis.  Regulations on how recreational marijuana can be advertised and marketed, distributed and the kind of insurance coverage necessary for dispensaries.  Additionally, employer drug-testing and marijuana statutes have been a hot area of litigation covered by the National Law Review.  

General practices in marketing standards, compliance of federal and state laws/legislation, licensing collaborations, and news related to bringing new products to the market, in the US and abroad, are among the areas visitors to NLR will read about daily. Drug pricing, changes in production standards, regulatory compliance, food safety and handling, drug laws (legalization of marijuana, both recreational and medicinal in the workplace), and labeling and nutritional requirements, are among the many topics covered by the National Law Review daily.

Visitors will always find the latest, up-to-date, most comprehensive coverage on the site. And, news and stories which affect the US, companies which are regulated in the industry, and multinational/international companies, are detailed regularly for NLR readers.

National Law Review Cannabis TwitterFor hourly updates on the latest news about biotech, food & drug, and cannabis laws, regulations, and legislation, be sure to follow our Cannabis X (formerly Twitter) feed, and sign up for complimentary e-news bulletins.

Recent Biotechnology, Food & Drug Administration FDA News

Title
Publication Date Organization
Feb
17
2016
FCA Claims Based on Average Wholesale Price Theory Barred by Public Disclosure Bar McDermott Will & Emery
Feb
17
2016
Cannabis-Related Contract Enforcement: Solution Presents Itself? Wilson Elser Moskowitz Edelman & Dicker LLP
Feb
17
2016
Menu Labeling in the House: FDA Requirements Keller and Heckman LLP
Feb
16
2016
CMS Notifies States of AMP Rule Requirements: 340B Providers Should Take Note Mintz
Feb
16
2016
Gluten-Free Go-Round re: Food Labeling Keller and Heckman LLP
Feb
13
2016
USDA Announces New Standards to Reduce Salmonella and Campylobacter in Poultry Morgan, Lewis & Bockius LLP
Feb
13
2016
CMA Fines GlaxoSmithKline and Several Generic Companies £45 million for Delaying Market Entry of Generic Paroxetine in the UK Covington & Burling LLP
Feb
12
2016
FDA Issues Draft Guidance for Connected Medical Devices Jackson Lewis P.C.
Feb
12
2016
TTB Issues Ruling on Category Management under Federal Tied-House Statute McDermott Will & Emery
Feb
12
2016
Cannabidiol: (Clinical) Trials and Tribulations Keller and Heckman LLP
Feb
12
2016
What the Administration Actually Can Do on Drug Pricing Mintz
Feb
11
2016
FDA Panel Shows Strong Support for Remicade Biosimilar Foley & Lardner LLP
Feb
11
2016
Recent Revisions to Internal Revenue Code Affecting Alcohol Beverages McDermott Will & Emery
Feb
11
2016
Soda Shakedown re: Sugar Tax Keller and Heckman LLP
Feb
11
2016
Remicade Biosimilar Closer To Approval, But Patent Dance Goes On Foley & Lardner LLP
Feb
10
2016
Positive FDA Advisory Committee Vote for First Monoclonal Antibody Biosimilar – But Will Patent Dispute Delay Launch? Mintz
Feb
10
2016
Drug Shortages are Forcing Treatments to be Rationed Stark & Stark
Feb
10
2016
FDA Unveils Action Plan to Combat Opioid Abuse Foley & Lardner LLP
Feb
10
2016
First Monoclonal Antibody Biosimilar in U.S. Gets One Step Closer to FDA Approval Mintz
Feb
10
2016
PTAB Institutes Trial On Previously Challenged Cabilly Patent Foley & Lardner LLP
Feb
10
2016
Deciphering Final AMP Rule – Key Provisions Impacting Pharmacies, PBMs, and Manufacturers Mintz
Feb
10
2016
FDA Food Funding for FY 2017 Keller and Heckman LLP
Feb
10
2016
USDA Declares “Do-Over” on Overhaul of Biotechnology Regulations Beveridge & Diamond PC
Feb
9
2016
FDA Issues Draft Guidance on ‘Emerging Signals’ Morgan, Lewis & Bockius LLP
Feb
9
2016
Cheese Controls re: FDA Safety Criteria Keller and Heckman LLP
Feb
8
2016
California Court Curbs Chipotle GMO Case Keller and Heckman LLP
Feb
5
2016
China Food Law: Year in Review 2015 Part II Keller and Heckman LLP
Feb
5
2016
Sounds Fishy: New Seafood Traceability Program Keller and Heckman LLP
 

NLR Logo

We collaborate with the world's leading lawyers to deliver news tailored for you. Sign Up to receive our free e-Newsbulletins

 

Sign Up for e-NewsBulletins